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Objective: To demonstrate in a mouse model of tuberculosis that excess iron load enhances the growth of 
Mycobacterium tuberculosis and to assess whether or not iron chelation may abrogate the effect of iron loading on 
Mycobacterium tuberculosis growth in the mouse model. 
Methods: In the first experiment, female BALB/C mice were infected intravenously with 5 . 4 ~  lo4 CFU of M. tuberculosis 
H37Rv per mouse. Before infection, half of them were treated for 2 weeks with 50 mg/kg polymaltose ferric hydroxide, 
a source of iron. In a second experiment, female BALB/C mice were infected intravenously with 9x104 CFU per mouse 
and half of them were iron loaded for 2 weeks before infection. Both iron-loaded and non-iron-loaded mice were treated 
with desferrioxamine (DFO), an iron chelator, or isoniazid. At each sacrifice, mice and their spleens were weighed, lung 
lesions were noted, and the number of M. tuberculosis CFU determined by quantitative cultures of spleen and lungs. 
Results: In the first experiment, the number of CFU was significantly higher in the spleen of iron-treated mice than in 
non-iron-loaded mice at days 14 and 28 after infection. In the second experiment, iron loading enhanced the 
multiplication of M. tuberculosis in the spleen but not in the lungs, DFO displayed a modest but significant effect on the 
multiplication of M. tuberculosis in iron-loaded mice, and isoniazid therapy was effective in both iron-loaded and non- 
iron-loaded mice. 
Conclusions: Iron loading of BALB/C mice enhanced the multiplication of M. tuberculosis in the spleens but not in the 
lungs. DFO exhibited significant activity against M. tuberculosis in iron-loaded mice, and isoniazid therapy was strongly 
bactericidal in both iron-loaded and non-iron-loaded mice. 
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INTRODUCTION 
Iron is required for the growth of nearly all forms of 
bacterial, fungal, protozoal, plant and animal cells. 
Vertebrate animals have developed elaborate strategies 
to withhold growth-essential iron from microbial 
invaders while retaining their own access to the metal 
[l]. HIV infection produces changes in iron meta- 
bolism that resemble those seen in many chronic 
inflammatory conditions [3]. These include a reduction 
of extracellular (transferrin-bound) iron in the serum 
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and accumulation of iron in macrophages at sites of 
storage such as the liver and spleen [3] .  These changes 
may help to limit the growth of extracellular infectious 
agents but not the intracellular ones that are so often 
associated with HIV infection. Iron excess in the 
macrophages might have a negative role not only by 
promoting the growth of microorganisms that inhabit 
macrophages but also by impairing immune defense 
mechanisms 11-51, This may be of particular import- 
ance when considering HIV-related tuberculosis. 
Several in vitro studies point to a growth-promoting 
effect of iron, as opposed to a growth-inhibitory effect 
of normal human serum or of an iron chelator on 
Mycobacterium tirberculosis [6-81. Moreover, several 
retrospective studies indicate that an iron excess, related 
either to the administration of exogenous iron or to 
African iron overload, is deleterious to the outcome of 
human tuberculosis [9,10]. Finally, a recent retro- 
spective study in HIV-infected patients showed that 
mycobacterial infections, including tuberculosis, were 
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more common in patients with high macrophage iron 
grades than in those with low to normal macrophage 
iron grades [l l] .  Astonishingly, the effect of the iron 
status of the host on the course of tuberculosis has not 
been examined in a murine model, apart from a very 
preliminary experiment reported more than 25 years 
ago [7]. The aim of the present study was therefore to 
study the outcome of tuberculosis in mice with 
different iron status. 
In a first experiment we examined whether or not 
iron overloading of mice enhanced the multiplication 
of M. tuberculosis. As the results of the first experiment 
suggested that this was the case, a second experiment 
was designed to confirm the enhancement and to 
determine whether the use of an iron chelator might 
abrogate this effect. In addition, the impact of iron 
loading on the antituberculosis activity of isoniazid was 
measured. 
MATERIALS AND METHODS 
First experiment 
Ninety female BALB/C mice, 6 weeks old, were 
infected intravenously with 5.4X104 CFU of M. 
tuberculosis H37Rv. During the 2 weeks preceding 
infection, half of the mice (controls) were given, 
intraperitonally, three times a week, 0.2 mL of normal 
saline, and the other half (test mice) were iron-loaded 
with 50 mg/kg polymaltose ferric hydroxide (PFH) 
given intraperitonally, three times a week, in a volume 
of 0.2 mL. 
To monitor the growth of M. tuberculosis in mice, 
15 control mice and 15 iron-loaded test mice were 
sacrificed the day after infection (Dl), and on days 14 
(D14) and 28 (D28) after infection, respectively. At 
each sacrifice, mice and their spleens were weighed, 
lung lesions noted, and CFU counts of M. tuberculosis 
performed by quantitative cultures of spleen and 
lungs. 
Second experiment 
One hundred and eighty female BALB/C mice, 8 
weeks old, were included in the second experiment and 
distributed into three subgroups. The 60 mice of the 
first subgroup were the uninfected controls: 30 were 
iron-loaded with 50 mg/kg PFH given in the volume 
of 0.2 mL, intraperitonally, three times a week, for 2 
weeks from D14 to DO before the beginning of the 
experiment; the other 30 were kept without treatment. 
The 60 mice of the second subgroup, considered to be 
the infected control mice, were infected on DO of the 
experiment with 9 X lo4 CFU of the M.  tuberculosis 
H37Rv strain. Then, 30 were given 0.2 mL of normal 
s&ne intraperitonally, three times a week, from D1 to 
D42 after infection; 20 were given intraperitonally, 
three times a week, 100 mg/kg desferrioxamine (DFO) 
in a volume of 0.2 mL from D1 to D42 after infection; 
the remaining 10 were orally treated with 25 mg/kg 
isoniazid from D14 to D42. The 60 mice of the third 
subgroup, considered as the test mice, were also 
infected on DO of the experiment with 9X lo4 CFU of 
the M. tuberculosis H37Rv strain. However, all had been 
given 50 mg/kg PFH intraperitonally, three times a 
week, for 2 weeks before infection; after infection, 30 
were left without treatment, 20 were given DFO 
100 mg/kg intraperitoneally in a volume of 0.2 mL, 
three times a week from D1 to D42, and the remaining 
10 were given oral isoniazid 25 mg/kg from D14 to 
D42 after infection. 
To monitor the impact of iron loading on the body 
weight and spleen weight of mice, 10 uninfected non- 
iron-loaded and 10 uninfected iron-loaded control 
mice were sacrificed at D1, D14 and D42 of the 
experiment. To monitor the growth of M.  tuberculosis, 
10 non-iron-loaded mice and 10 iron-loaded mice 
were sacrificed on D1, D14 and D42 after infection. 
At each sacrifice, mice and their spleens were weighed, 
lung lesions were noted, and CFU counts of M. 
tuberculosis performed by quantitative cultures of spleen 
and lungs. 
Bacterial strain and infection 
The virulent H37Rv strain of M. tuberculosis was 
passaged regularly through mice to maintain its 
virulence. Each mouse was infected intravenously with 
0.5 mL of a diluted Dubos broth containing 5.4X104 
CFU for the first experiment and 9X104 CFU of 
H37Rv strain for the second experiment, as deter- 
mined by CFU counts on Lowenstein-Jensen medium. 
The minimal inhibitory concentration of isoniazid was 
0.05 mg/L for the H37Rv strain. 
Drugs for treatment 
For the treatment of mice, PFH from Therabel Lucien 
Pharma, Neuilly, France and DFO from Ciba-Geigy 
(Novartis), Rueil-Malmaison, France were used, and 
isoniazid was generously provided by Roche, Neuilly, 
France. 
Assessment of results 
In both mouse experiments, the parameters for 
assessing the severity of infection and the effectiveness 
of treatment were the CFU counts in spleens and lungs, 
the body and spleen weights, and the gross lung lesions. 
The severity of gross lung lesions was scored from 0 to 
2+,  with the latter referring to a lung extensively 
infiltrated with tubercles [12]. 
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Enumeration of CFU in the organs 
At the time of sacrifice, the organs were removed 
aseptically and were homogenized by a standard 
procedure [13], and the suspensions were made up to 
3.5 mL for each organ. At least three serial 10-fold 
dilutions of the suspensions were plated in triplicate on 
Lowenstein-Jensen medium. The results of the cultures 
were recorded after incubation at 37°C for 6 weeks. 
Statistical analysis 
Multiple comparisons among pairs of groups means 
were performed by Bonferroni’s method [14]. In the 
first experiment, two groups were compared and 
differences were considered significant at the level of 
0.05. In the second experiment, because the results 
from six groups were compared, differences were 
considered significant at the level of 0.00333, i.e. 
0.05/[6(6- 1)/2].The mean values of spleen weights 
and CFU were given with their standard deviation. 
RESULTS 
First experiment 
Survival rate 
There were three deaths among the non-iron-loaded 
control mice that occurred respectively at D2, D7 and 
D17 after infection. None of them was related to the 
tuberculosis infection. A single mouse died on D7 
among the iron-loaded mice. 
Evolution of body and spleen weights 
During the experiment, there was no significant 
difference between the body weight of iron-loaded 
infected inice and that of non-iron-loaded infected 
mice sacrificed on D1 (15.9 g compared to 17.3 g), 
D14 (18.1 g compared to 18.3 g) and D28 (19.7 g 
compared to 18.9 g) after infection. The spleen weights 
of iron-loaded and non-iron-loaded mice were similar 
on D1 after infection, 73.1 mg and 75.3 mg respec- 
tively. However, on D14 and D28 after infection, the 
spleen weights of the iron-loaded mice were signifi- 
cantly higher than those of the non-iron-loaded mice, 
382.2 mg compared to 213.8 mg on D14, and 373 mg 
compared to 249.9 mg on D28, respectively. 
Lung gross lesions 
None of the iron-loaded or non-iron-loaded mice 
displayed gross lung lesions on D1 and D11 after 
infection, but 11 of 12 surviving mice of the non-iron- 
loaded group and all surviving mice of the iron-loaded 
group displayed gross lung lesions of moderate severity 
on D28. 
Table 1 Mean CFU counts in the spleens and lungs of mice infected or not, loaded or 
not with iron, and trcated or not with desferrioxamine (DFO) or isoniazid 
Time after 
infection 
Mean CFU (logi~) per: 
Group Spleen Lungs 
First experiment 
D1 
D1 
D14 
D14 
D28 
D28 
Second experiment 
D1 
D1 
D14 
D14 
D14 
D14 
D42 
D42 
D42 
D42 
D42 
D-12 
Control 
Iron 
Control 
Iron 
Control 
Iron 
Control 
Iron 
Control 
Iron 
DFO 
Iron+DFO 
Control 
Iron 
DFO 
Iron + DFO 
Isoniazid 
Iron+ Isoniazid 
3.31f0.16 
3.2620.28 
5.83f0.18a 
6.08f0.20’ 
4.89+0.13h 
5.70?0.20b 
3.7620. 18 
3.96f0.09 
6.59a0.32 
7.1020.11 
6.5120.29 
6.8120.18 
5.9820.26 
6.9120.14 
5.63k0.28 
6.62f0.14 
3.77 f 0.2 1 
4.58f0.27 
2.13f0.61 
1.8820.27 
3.90f0.29 
4.05f0.36 
4.41 20.44 
4.60a0.51 
2.0920.18 
1.69f0.34 
4.97f0.25 
4.93f0.35 
4.89f0.18 
4.8320.35 
5.175023 
5.14a0.33 
5.0120.29 
5.62f0.21 
2.47 k0.27 
2.72+0.-13 
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CFU counts in spleen and lungs 
On D1 after infection, there was no significant differ- 
ence between the CFU counts in the iron-loaded and 
the non-iron-loaded mice. However, as shown in Table 
1, on D14 and D28 after infection, the CFU counts 
were significantly higher in the spleen of iron-loaded 
mice than in the spleen of non-iron-loaded mice. 
Conversely, there was no significant difference in the 
CFU counts between the lungs of iron-loaded and 
those of non-iron-loaded mice, either on D14 or on 
D28. 
Second experiment 
Survival rate 
All mice survived infection and treatment except for a 
single mouse from the iron-loaded group, infected and 
treated with DFO, that died on D15 after infection, 
most likely due to an accident caused by the 
intraperitoneal injection of DFO. 
Evolution of the body and spleen weights 
The mean body weight increased without significant 
difference on D1, D14 and D42 after infection in 
infected and non-infected, iron-loaded and non-iron- 
loaded mice treated either with DFO or with isoniazid, 
or not treated at all. 
The spleen weights were not significantly different 
on D1 after infection between the iron-loaded and the 
non-iron-loaded mice. However, on D14 and D42 
after infection, they were significantly higher in iron- 
loaded mice than in non-iron-loaded ones. As shown 
in Table 2, the treatment with DFO had no impact on 
the spleen weights of iron-loaded and non-iron-loaded 
mice on D14 as well as on D42. Conversely, the treat- 
ment with isoniazid significantly reduced the spleen 
weights of iron-loaded and non-iron-loaded mice on 
D42 compared with the spleen weights on D14, but 
did not compensate for the iron load: on D42, the 
spleen weights were significantly higher in iron-loaded 
mice than in non-iron-loaded mice. The difference 
between iron-loaded and non-iron-loaded infected 
mice is only partly related to infection, because un- 
infected iron-loaded mice had, on D42, spleen weights 
significantly higher than those of uninfected non-iron- 
loaded mice. 
Gross lung lesions 
None of the mice displayed gross lung lesions on D1 
and D14 after infection, but every mouse of all infected 
groups, except those treated with isoniazid, in which 
there was no lesion at all, had gross lung lesions of 
moderate severity on D42 after infection. 
CFU counts in spleen and lungs 
In the spleen, there was no significant difference on D1 
after infection in the CFU counts between iron-loaded 
and non-iron-loaded mice (Table 1). On D14, the 
CFU counts were significantly higher in iron-loaded 
mice than in non-iron-loaded mice. Between D14 
and D42, because of the development of the specific 
immune response, the CFU counts decreased slightly 
in both groups of mice, the difference between 
iron-loaded and non-iron-loaded mice remaining 
significant. Treatment with DFO reduced slightly but 
significantly on D14 and D42 the CFU counts in the 
spleen of iron-loaded mice, whereas it had no 
significant effect in the spleen of non-iron-loaded mice. 
As shown in Table 1, treatment with isoniazid reduced 
significantly, and in a parallel manner, the CFU counts 
by more than 2 loglo in both iron-loaded and non-iron- 
loaded mice. As a result, on D42, the CFU counts were 
Table 2 Mean spleen weight of m i c e  infected or not, loaded or not with iron, and 
treated or not with DFO or isoniazid in the second experiment 
~ ~~ 
Mean spleen weight (mg) on the follomng dates of sacrifice 
Groups D1 D14 D42 
Non-infected m c e  92210 101217 11 1212’ 
Non-infected+ Iron 9229 117212 150215” 
Infected and untreated 92214 353240b 36423sb 
Infected+DFO - 350549b 311?33b 
Infected+Isoniazid - - 188k17 
Infected + Iron 
Infected+Iron+DFO 
107+-15 447f46‘ 434k43‘ 
- 454539‘ 474 5 76‘ 
- 246220 Infected+ Iron+ Isoniazid - 
ap<0.05; bpz0.05; ‘p>0.05; a versus ‘p<0.05 
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still higher in isoniazid-treated iron-loaded mice than 
in isoniazid-treated non-iron-loaded mice. 
In the lungs, as in the spleen, on D 1 after infection 
the CFU counts were not significantly different in iron- 
loaded and non-iron-loaded mice. However, in con- 
trast to the CFU counts in the spleen, from D 1 to D 14 
and D42, the CFU counts in lungs increased equally by 
3 loglo in iron-loaded and non-iron-loaded mice. 
Treatment with DFO was without effect, and treatment 
with isoniazid reduced CFU counts by more than 2 
loglo in both groups of mice. 
DISCUSSION 
Our study demonstrates that the growth of M.  
tuberculosis in BALB/C mice was significantly increased 
in the spleen but not in the lungs when the animals 
were previously iron-loaded. It also demonstrates that 
DFO, an iron chelator, reduced partially, though 
significantly, the iron-related enhanced microbial 
growth in the spleen; and the bactericidal effect of 
isoniazid therapy was not impaired by the iron loading. 
No other study on the impact of iron on murine 
tuberculosis has been reported so far, except for a 
preliminary study from Kochan 171, in which the 
growth of Ail. tuberculosis H37Rv in the spleen was 
enhanced when the mice had been preloaded with 
iron. Thus the results of our study confirm Kochan’s 
findings, emphasizing that the iron-induced increase 
was observed in the spleen but not in the lungs. One 
possible explanation for the tissue difference might be 
a higher degree of iron accumulation in the spleen than 
in lungs after experimental administration of iron-sugar 
complexes [ 151. However, increased multiplication of 
hf. uvium occurred in lungs as well as in liver and spleen 
of mice given iron-supplemented laboratory chow 
[161. 
The existence of a link between iron meta- 
bolism and the Nrarnpl gene that mediates the innate 
resistance against mycobacterial growth has been 
recently raised [17]. The addition of iron to macro- 
phages from BCG-susceptible (BCGs) mice resulted in 
stimulation of M .  avium growth. In contrast, iron 
increased the capacity of macrophages from BCG- 
resistant (BCGr) mice to control the growth of M. 
avium [18]. As BALB/C mice belong to the BCGs 
strains, there is agreement between our findings and 
those obtained with macrophages. I t  would be of 
interest to determine whether iron loading of BCGr 
mice, e.g. C3H, would increase the innate resistance of 
these mice to tuberculosis. 
DFO is the standard of iron chelation therapy 
and is the chelator currently used to treat patients with 
iron overload [ 191. An important item of information 
provided by our second experiment is the significant 
reduction of M .  tuberculosis multiplication resulting 
from the DFO therapy of the iron-loaded mice. The 
inhibitory effect of iron chelation on the growth of 
many microorganisms, even in the absence of iron 
overload, and on the course of experimental infections 
is well known 1201. In mycobacterial infections, DFO 
was found to suppress M .  aviuiu growth in vitro, when 
studied both in axenic medium and in murine 
macrophages [21,22]. In our experiment, DFO was 
given three times weekly, intraperitonally, at a dose of 
100 mg/kg, and its efficacy against M. tuberculosis in 
iron-loaded mice, although significant, was modest. In 
humans, the recommended dosage for the treatment 
of secondary hemochromatosis or hemosiderosis is 
40 mg/kg daily by the subcutaneous route [19]. 
Compared to the effective dose in humans and in other 
experimental infections [23], the dose we used was 
rather low, and this may explain why the DFO therapy 
resulted in a modest benefit only. As the equipotent 
drug dosage in the mouse is on average 10-17 times the 
human dosage [24], one may wonder whether a dosage 
of 400 mg/kg DFO would not result in more pro- 
nounced antituberculosis activity. 
Even though iron overload favored the growth of 
M.  tuberculosis, our experimental findings did not 
suggest that it might impair the response to antibiotic 
therapy of tuberculosis in patients with high iron 
content. Actually the response to isoniazid therapy was 
as good in iron-loaded mice as in non-iron-loaded 
mice, the microbial killing being more than 2 loglo at 
1 month in both groups of mice. However, as iron- 
loaded mice initially had one loglo more CFU than 
non-iron-loaded mice, after 1 month of equally 
effective isoniazid therapy, iron-loaded mice were still 
harboring 1 loglo more CFU than non-iron-loaded 
mice. Consequently, to reduce the microbial popu- 
lation to the same level of CFU, the therapy would 
require a longer duration in iron-loaded mice than in 
normal mice.The same reasoning might be applied to 
the therapy of tuberculosis in patients with an excess of 
iron, such as many HIV-positive patients, and the 
duration of the initial intensive phase of therapy might 
need to be prolonged beyond 2 months in some HIV- 
coinfected tuberculosis patients. 
In conclusion, our study provides additional infor- 
mation on the negative effect of iron in excess on  the 
course of tuberculosis, and it underscores the concept 
of iron withholding in the host defense to micro- 
organisms [l]. In view of the growing importance of 
tuberculosis worldwide, more work is required to study 
whether this concept may find clinical application in 
the field of human tuberculosis. 
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